The Effect of SAAE on Ventricular Remodeling in PA Patients
ConditionPrimary Aldosteronism
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorSecond Affiliated Hospital of Nanchang University
About this trial
The study aims to assess the effect of superselective adrenal arterial embolization on ventricular remodeling in primary aldosteronism without lateralized aldosterone secretion by comparing it with spironolactone therapy.
Eligibility criteria
Qualifiers
(1) Age 18-60 years old, regardless of gender;
(2) Blood pressure conditions meet one of the following: 1) Office blood pressure ≥ 140/90mmHg; 2) Ambulatory blood pressure monitoring whole day blood pressure > 130/80 mmHg or daytime blood pressure > 135/85 mmHg;
(3) After strict drug elution, it met the diagnostic criteria of primary aldosteronism, and bilateral primary aldosteronism was confirmed by adrenal venous sampling;
(4) No surgical intent or contraindication to surgery and willing to undergo pharmacological treatment or percutaneous superselective adrenal artery embolization;
Disqualifiers
(1) Primary hypertension or secondary hypertension with other causes;
(2) A woman who is pregnant or lactating, or has a birth plan for the next year;
(3) There are serious organic diseases, especially liver and kidney dysfunction(eGFR<45 mL/min/1.73 m2);
(4) Severe allergy to contrast medium;
Trial design
Treatments tested in this trial
- Super selective adrenal artery embolization
- Spironolactone
Treatment groups
112 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov